. Author manuscript; available in PMC: 2014 Jun 2.

Published in final edited form as: J Am Coll Cardiol. 2012 Oct 16;60(16):1558–1565. doi: 10.1016/j.jacc.2012.05.049

Table 4.

Univariate and Multivariate Analysis in Normotensive and Pre-Hypertensive Subjects Not on Antihypertension Medications

Biomarker	Univariate Model (� ± SE)	Model 1 (� ± SE)	Model 2 (� ± SE)	Model 3 (� ± SE)	Model 4 (� ± SE)
Log proBNP_1–108	0.03 ±0.07	−0.00 ±0.07	0.02 ±0.07	0.02 ±0.07	0.02 ±0.07
Log BNP_1–32 (Shionogi)	0.04 ±0.07	−0.01 ±0.06	−0.00 ±0.06	0.00 ±0.06	0.00 ±0.06
Log BNP_1–32 (Biosite)	−0.06 ±0.08	−0.07 ±0.07	−0.05 ±0.07	−0.05 ±0.07	−0.05 ±0.07
Log NT-proBNP_1–76 (Roche)	−0.06 ±0.08	−0.08 ±0.07	−0.06 ±0.07	−0.06 ±0.07	−0.06 ±0.07
Log ANP_1–28 (Phoenix Pharmaceuticals)	0.02 ±0.05	0.01 ±0.05	0.03 ±0.05	0.03 ±0.05	0.03 ±0.05

Log NT-ANP_1–98 (Phoenix Pharmaceuticals)	−0.08 ±0.05	−0.12 ±0.04^*	−0.10 ±0.04^*	−0.09 ±0.04^*	−0.08 ±0.04

Values are 1 ± SE in contrast to normotensive subjects. Model 1 = age+age²+sex; Model 2 = age+age²+sex+BMI; Model 3 = age+age²+sex+BMI+LVH; Model 4 = age+age²+sex+BMI+LVH+creatinine. Logarithm of BNP and ANP values used to satisfy regression assumptions.

p < 0.05.

Abbreviations as in Table 1.